Literature DB >> 8160904

Peritoneal cultures and antibiotic therapy in pediatric perforated appendicitis.

D M Mosdell1, D M Morris, D E Fry.   

Abstract

We retrospectively reviewed 70 cases of perforated appendicitis in children to examine the relationship between postoperative antibiotic selection and culture results from the peritoneal cavity. Initial antibiotic therapy chosen for the children consisted of a three-drug combination in 54 (77%) patients. Peritoneal cultures were performed in 58 (83%) patients. Escherichia coli and Bacteriodes fragilis were the most common bacterial isolates from the peritoneal culture. Only 7 (10%) patients had their antibiotic regimen changed after the culture results were available, of which 2 changes brought drug therapy into compliance with the cultures and 5 changes were inappropriate with respect to the peritoneal cultures. Of the remaining 51 patients with culture data available, 39 should have had changes to bring the antibiotic therapy into compliance with the observed culture results. These data indicate that surgeons select antibiotic therapy for perforated appendicitis in children based on assumptions of which organisms should be present in the infection and not on culture data. There appears to be no clinical usefulness to the routine culturing of the peritoneal cavity in children with perforated appendicitis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8160904     DOI: 10.1016/0002-9610(94)90207-0

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  10 in total

1.  Determinants of postoperative abscess occurrence and percutaneous drainage in children with perforated appendicitis.

Authors:  Sherif Emil; Sherif Elkady; Layla Shbat; Fouad Youssef; Robert Baird; Jean-Martin Laberge; Pramod Puligandla; Kenneth Shaw
Journal:  Pediatr Surg Int       Date:  2014-11-02       Impact factor: 1.827

Review 2.  Management of secondary peritonitis.

Authors:  D H Wittmann; M Schein; R E Condon
Journal:  Ann Surg       Date:  1996-07       Impact factor: 12.969

3.  Comparative Effectiveness of Ceftriaxone plus Metronidazole versus Anti-Pseudomonal Antibiotics for Perforated Appendicitis in Children.

Authors:  Rana F Hamdy; Lori K Handy; Evangelos Spyridakis; Daniele Dona; Matthew Bryan; Joy L Collins; Jeffrey S Gerber
Journal:  Surg Infect (Larchmt)       Date:  2019-03-15       Impact factor: 2.150

Review 4.  Minimum postoperative antibiotic duration in advanced appendicitis in children: a review.

Authors:  Carolyn M H Snelling; Dan Poenaru; John W Drover
Journal:  Pediatr Surg Int       Date:  2004-10-06       Impact factor: 1.827

5.  Once Daily Dosing of Ceftriaxone and Metronidazole in Children With Perforated Appendicitis.

Authors:  Ji Yeon Lee; Saudia Ally; Brian Kelly; David Kays; Lisa Thames
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr

6.  Is it justified to obtain routine peritoneal fluid cultures during appendectomy in children?

Authors:  A Celik; O Ergün; C Ozcan; H Aldemir; E Balik
Journal:  Pediatr Surg Int       Date:  2003-11-12       Impact factor: 1.827

7.  Are routine peritoneal fluid cultures during appendicectomy justified?

Authors:  M N Khan; R Vidya; R E Lee
Journal:  Ir J Med Sci       Date:  2007-03       Impact factor: 1.568

8.  The need for culture swabs in laparoscopically treated appendicitis.

Authors:  Jakub Kenig; Piotr Richter
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2013-05-07       Impact factor: 1.195

9.  Diagnosis and treatment of acute appendicitis in children: a survey among Dutch surgeons and comparison with evidence-based practice.

Authors:  E C T H Tan; R S V M Severijnen; C Rosman; G J van der Wilt; H van Goor
Journal:  World J Surg       Date:  2006-04       Impact factor: 3.282

10.  The efficacy of combined therapy with metronidazole and broad-spectrum antibiotics on postoperative outcomes for pediatric patients with perforated appendicitis.

Authors:  Qingjuan Shang; Qiankun Geng; Xuebing Zhang; Chunbao Guo
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.